TDI 208

Scientists at the ALS Therapy Development Institute are testing this small molecule in an attempt to address the oxidative stress observed in the cells of PALS.


Type: Small Molecule
Stage: Active
Status: Active
Sponsor: ALS Therapy Development Institute

TDI Says:

This potential treatment was added to our pipeline in 2015 and is currently undergoing important experiments. These tests will help us better understand its pharmacokinetics and allow us to determine a prudent dosing strategy in efficacy testing.

Comment on this Topic

(All comments are moderated before they appear here.)
Combined Federal Campaign
Work for the Federal Government? Support ALS
research by joining the Combined Federal Campaign.